EP2654794B8 - Materials and methods for conjugating a water soluble fatty acid derivative to a protein - Google Patents

Materials and methods for conjugating a water soluble fatty acid derivative to a protein Download PDF

Info

Publication number: EP2654794B8
Authority: EP; European Patent Office
Prior art keywords: conjugating; protein; materials; methods; fatty acid
Prior art date: 2010-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP11806103.5A

Other languages

German (de)

French (fr)

Other versions

EP2654794A1 (en

EP2654794B1 (en

Inventor

Juergen Siekmann

Richard SCHEINECKER

Hanspeter Rottensteiner

Peter Turecek

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxalta GmbH

Baxalta Inc

Original Assignee

Baxalta GmbH

Baxalta Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-22

Filing date

2011-12-16

Publication date

2020-04-22

2011-12-16 Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH

2011-12-16 Priority to PL11806103T priority Critical patent/PL2654794T3/en

2011-12-16 Priority to EP19211476.7A priority patent/EP3673921A1/en

2013-10-30 Publication of EP2654794A1 publication Critical patent/EP2654794A1/en

2020-03-04 Application granted granted Critical

2020-03-04 Publication of EP2654794B1 publication Critical patent/EP2654794B1/en

2020-04-22 Publication of EP2654794B8 publication Critical patent/EP2654794B8/en

Status Active legal-status Critical Current

2031-12-16 Anticipated expiration legal-status Critical

Links

230000001268 conjugating effect Effects 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 title 1
229930195729 fatty acid Natural products 0.000 title 1
239000000194 fatty acid Substances 0.000 title 1
150000004665 fatty acids Chemical class 0.000 title 1
239000000463 material Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

EP11806103.5A 2010-12-22 2011-12-16 Materials and methods for conjugating a water soluble fatty acid derivative to a protein Active EP2654794B8 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
PL11806103T PL2654794T3 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP19211476.7A EP3673921A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201061426356P	2010-12-22	2010-12-22
PCT/US2011/065591 WO2012087838A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP19211476.7A Division EP3673921A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP19211476.7A Division-Into EP3673921A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Publications (3)

Publication Number	Publication Date
EP2654794A1 EP2654794A1 (en)	2013-10-30
EP2654794B1 EP2654794B1 (en)	2020-03-04
EP2654794B8 true EP2654794B8 (en)	2020-04-22

Family

ID=45464916

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP11806103.5A Active EP2654794B8 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP19211476.7A Withdrawn EP3673921A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP19211476.7A Withdrawn EP3673921A1 (en)	2010-12-22	2011-12-16	Materials and methods for conjugating a water soluble fatty acid derivative to a protein

Country Status (20)

Country	Link
US (1)	US8945897B2 (en)
EP (2)	EP2654794B8 (en)
JP (1)	JP6138052B2 (en)
KR (1)	KR102025442B1 (en)
CN (1)	CN103269723B (en)
AR (1)	AR084576A1 (en)
AU (2)	AU2011349574B9 (en)
BR (1)	BR112013015898A2 (en)
CA (1)	CA2822591C (en)
DK (1)	DK2654794T3 (en)
EA (1)	EA032056B1 (en)
ES (1)	ES2800983T3 (en)
HU (1)	HUE049352T2 (en)
MX (1)	MX345608B (en)
NZ (1)	NZ612320A (en)
PL (1)	PL2654794T3 (en)
PT (1)	PT2654794T (en)
SG (1)	SG191298A1 (en)
TW (1)	TWI546279B (en)
WO (1)	WO2012087838A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2015535304A (en) *	2012-09-10	2015-12-10	ザ・ジョンズ・ホプキンス・ユニバーシティ	Microfluidic chip for solid-phase glycan and glycopeptide analysis, and glycomic extraction, analysis and methods for using the same
CN103897031A (en) *	2012-12-25	2014-07-02	深圳先进技术研究院	Chemically modified thymopentin and synthetic method thereof
US20140243220A1 (en) *	2013-02-25	2014-08-28	J. Craig Venter Institute	Metaproteomic Method to Identify Secreted Pattern Recognition Molecules and Adhesive Antimicrobial Factors for Detection of Microbial Agents Eliciting Inflammation in the Human Host
EP2976365A1 (en) *	2013-03-20	2016-01-27	Fresenius Kabi Deutschland GmbH	Process for the preparation of thiol functionalized hydroxyalkyl starch derivatives
CN103636918B (en) *	2013-12-13	2015-11-04	东北农业大学	One is rich in linoleic modification protein isolate preparation method
WO2015095553A1 (en)	2013-12-20	2015-06-25	Nephrogenesis, Llc	Methods and apparatus for kidney dialysis
EP2915569A1 (en) *	2014-03-03	2015-09-09	Cytune Pharma	IL-15/IL-15Ralpha based conjugates purification method
KR20180031775A (en) *	2015-08-12	2018-03-28	셀 머신스, 인크.	Methods and compositions related to long half-life aggregation complexes
CN106554425B (en) *	2015-09-18	2018-10-30	沈阳药科大学	A kind of lipid Grafted Derivatives of poly sialic acid and its application
US20180360973A1 (en) *	2015-12-02	2018-12-20	Hanmi Pharm. Co., Ltd.	Protein conjugate using a fatty acid derivative and method for preparation thereof
CN108147990B (en) *	2016-12-02	2023-01-24	上海中医药大学	Membrane anchoring element and application thereof
TW201837051A (en)	2017-02-08	2018-10-16	美商必治妥美雅史谷比公司	Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN107141354A (en) *	2017-05-05	2017-09-08	李斯文	A kind of fusion protein and sensitising agent compound and its preparation method and application
US11358994B2 (en)	2017-07-27	2022-06-14	Saint Louis University	Fatty acid modified human epidermal growth factor
RU2753880C1 (en) *	2017-09-19	2021-08-24	Иммунворк Инк.	Pharmaceutical structures with increased albumin binding affinity
CA3126476A1 (en)	2019-01-23	2020-07-30	Regeneron Pharmaceuticals, Inc.	Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US11845989B2 (en)	2019-01-23	2023-12-19	Regeneron Pharmaceuticals, Inc.	Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP3819307A1 (en) *	2019-11-07	2021-05-12	CytoKi Pharma ApS	Therapeutic derivatives of interleukin-22
US11692020B2 (en)	2019-11-20	2023-07-04	Anwita Biosciences, Inc.	Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
US11897930B2 (en)	2020-04-28	2024-02-13	Anwita Biosciences, Inc.	Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN113967267B (en) *	2020-07-21	2022-10-25	四川大学	Endoplasmic reticulum targeting of fatty acid modified albumin and uses thereof
EP4298219A1 (en)	2021-02-26	2024-01-03	Regeneron Pharmaceuticals, Inc.	Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
EP4089107A1 (en) *	2021-05-11	2022-11-16	CytoKi Pharma ApS	Therapeutic derivatives of interleukin-22
JP2024517327A (en) *	2021-05-11	2024-04-19	サイトカイ・ファーマ・アーペーエス	Therapeutic Derivatives of Interleukin-22
EP4089108A1 (en) *	2021-05-11	2022-11-16	CytoKi Pharma ApS	Therapeutic derivatives of interleukin-22
CN114990175B (en) *	2021-10-22	2023-03-31	岩唐生物科技(杭州)有限责任公司	Synthesis method of fucose derivatives
WO2024026099A1 (en) *	2022-07-29	2024-02-01	The Trustees Of The University Of Pennsylvania	Lymphatic targeted anti-coagulant for the prevention of lymphatic thrombosis

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS54113492A (en)	1978-02-24	1979-09-05	Sanyo Chem Ind Ltd	Preparation of glucoprotein derivative
US4356170A (en)	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
US5198349A (en)	1986-01-03	1993-03-30	Genetics Institute, Inc.	Method for producing factor VIII:C and analogs
US5250421A (en)	1986-01-03	1993-10-05	Genetics Institute, Inc.	Method for producing factor VIII:C-type proteins
JPH0387173A (en)	1987-09-10	1991-04-11	Teijin Ltd	Preparation of human active natural type factor viii c and transformant using the same
US5153265A (en)	1988-01-20	1992-10-06	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US4966999A (en)	1988-06-07	1990-10-30	Cytogen Corporation	Radiohalogenated compounds for site specific labeling
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (en)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	A recombinant human factor VIII derivative and process for its preparation
SE466754B (en)	1990-09-13	1992-03-30	Berol Nobel Ab	COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES
EP0513332A4 (en)	1990-11-14	1993-03-17	Cargill, Incorporated	Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
JPH06506217A (en)	1991-03-18	1994-07-14	エンゾン，インコーポレーテッド	Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
US5846951A (en)	1991-06-06	1998-12-08	The School Of Pharmacy, University Of London	Pharmaceutical compositions
US6037452A (en)	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994005332A2 (en)	1992-09-01	1994-03-17	Berlex Laboratories, Inc.	Glycolation of glycosylated macromolecules
CA2124690C (en)	1992-10-02	2007-09-11	Thomas Osterberg	Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
NZ250375A (en)	1992-12-09	1995-07-26	Ortho Pharma Corp	Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en)	1992-12-22	1994-03-29	Enzon, Inc.	Aryl imidate activated polyalkylene oxides
AU6029594A (en)	1993-01-15	1994-08-15	Enzon, Inc.	Factor viii - polymeric conjugates
US5621039A (en)	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
SE504074C2 (en)	1993-07-05	1996-11-04	Pharmacia Ab	Protein preparation for subcutaneous, intramuscular or intradermal administration
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
WO1995007931A1 (en)	1993-09-17	1995-03-23	Novo Nordisk A/S	Acylated insulin
CA2204726A1 (en)	1994-11-09	1996-12-27	Robin E. Offord	Functionalized polymers for site-specific attachment
WO1996040731A1 (en)	1995-06-07	1996-12-19	Mount Sinai School Of Medicine Of The City University Of New York	Pegylated modified proteins
WO1996040662A2 (en)	1995-06-07	1996-12-19	Cellpro, Incorporated	Aminooxy-containing linker compounds and their application in conjugates
SE9503380D0 (en)	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
US5866538A (en)	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
CA2288992C (en)	1997-04-30	2012-06-12	Enzon, Inc.	Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6183738B1 (en)	1997-05-12	2001-02-06	Phoenix Pharamacologics, Inc.	Modified arginine deiminase
EP1012259B1 (en)	1997-06-04	2009-09-30	Oxford Biomedica (UK) Limited	Tumor targeted vector
US6531298B2 (en)	1997-07-21	2003-03-11	The University Of North Carolina At Chapel Hill	Factor IX antihemophilic factor with increased clotting activity
WO2001082943A2 (en)	2000-05-03	2001-11-08	Novo Nordisk A/S	Subcutaneous administration of coagulation factor vii
DE59813187D1 (en)	1997-12-03	2005-12-15	Roche Diagnostics Gmbh	PROCESS FOR THE PREPARATION OF POLYPEPTIDES WITH APPROPRIATE GLYCOSILATION
US5985263A (en)	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
US6596398B1 (en)	1998-08-21	2003-07-22	Atofina Chemicals, Inc.	Solar control coated glass
DK1400551T3 (en)	1998-08-28	2007-10-15	Amylin Pharmaceuticals Inc	Precise length polyamide chains and their proteins conjugates
EE04967B1 (en)	1998-10-16	2008-02-15	Biogen, Incorporated	Glycylated Interferon Beta, its Use and a Pharmaceutical Composition, Method for Prolonging Interferon Beta-1a Activity, and Preparing a Protein of the Invention
DE19852729A1 (en)	1998-11-16	2000-05-18	Werner Reutter	Recombinant glycoproteins, processes for their preparation, medicaments containing them and their use
JP5149470B2 (en)	1999-02-22	2013-02-20	バクスター・インターナショナル・インコーポレイテッド	Novel factor VIII formulation without albumin
WO2000075105A1 (en) *	1999-06-08	2000-12-14	La Jolla Pharmaceutical Company	Valency platform molecules comprising aminooxy groups
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
YU32402A (en)	1999-11-12	2005-03-15	Maxygen Holdings Ltd.	Interferon gamma conjugates
US7074878B1 (en)	1999-12-10	2006-07-11	Harris J Milton	Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en)	1999-12-23	2002-07-02	Shearwater Corporation	Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ES2325877T3 (en)	2000-02-11	2009-09-23	Bayer Healthcare Llc	FACTOR TYPE MOLECULES VII OR VIIA.
AU2001254624A1 (en)	2000-05-03	2001-11-12	Novo-Nordisk A/S	Human coagulation factor vii variants
AU2001268228A1 (en)	2000-06-08	2001-12-17	La Jolla Pharmaceutical Company	Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6423826B1 (en)	2000-06-30	2002-07-23	Regents Of The University Of Minnesota	High molecular weight derivatives of vitamin K-dependent polypeptides
US7118737B2 (en)	2000-09-08	2006-10-10	Amylin Pharmaceuticals, Inc.	Polymer-modified synthetic proteins
JP4361728B2 (en)	2000-09-13	2009-11-11	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Human coagulation factor VII mutant
DE60141908D1 (en)	2000-10-02	2010-06-02	Novo Nordisk Healthcare Ag	GLYCO FORMS OF FACTOR VII
GB0103877D0 (en) *	2001-02-16	2001-04-04	King S College London	Novel Drug Delivery system
CA2441580A1 (en)	2001-03-22	2002-10-03	Novo Nordisk Health Care Ag	Coagulation factor vii derivatives
US6913915B2 (en)	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
US6770625B2 (en) *	2001-09-07	2004-08-03	Nobex Corporation	Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2516041T3 (en)	2001-10-10	2014-10-30	Ratiopharm Gmbh	Remodeling and glycoconjugation of human growth hormone (hGH)
US7795210B2 (en)	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en)	2001-10-10	2007-09-04	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7026440B2 (en)	2001-11-07	2006-04-11	Nektar Therapeutics Al, Corporation	Branched polymers and their conjugates
WO2003045980A2 (en)	2001-11-28	2003-06-05	Neose Technologies, Inc.	Glycopeptide remodeling using amidases
DE60228492D1 (en)	2001-11-28	2008-10-02	Neose Technologies Inc	REMODELING OF GLYCOPROTEINS USING ENDOGLYCANASES
KR101186140B1 (en)	2002-06-21	2012-09-27	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Pegylated factor vii glycoforms
US7087229B2 (en)	2003-05-30	2006-08-08	Enzon Pharmaceuticals, Inc.	Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en)	2002-08-13	2006-10-17	Enzon, Inc.	Releasable polymeric conjugates based on aliphatic biodegradable linkers
AU2003253399B2 (en)	2002-09-11	2010-10-14	Fresenius Kabi Deutschland Gmbh	Hasylated polypeptides, especially hasylated erythropoietin
EP1681303B1 (en)	2002-09-11	2013-09-04	Fresenius Kabi Deutschland GmbH	HASylated polypeptides, especially HASylated erythropoietin
ES2214166T1 (en)	2002-09-11	2004-09-16	Fresenius Kabi Deutschland Gmbh	HAS-ILLATED POLYPEPTIDES, ESPECIALLY, HAS-ILADA ERIPTROPOYETINA.
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2003300133B2 (en)	2002-12-31	2008-11-13	Nektar Therapeutics	Hydrolytically stable maleimide-terminated polymers
ATE399185T1 (en)	2002-12-31	2008-07-15	Nektar Therapeutics Al Corp	MALEIC ACID AMIDE POLYMER DERIVATIVES AND THEIR BIOCONJUGATES
EP1596887B1 (en)	2003-02-26	2022-03-23	Nektar Therapeutics	Polymer-factor viii moiety conjugates
US7623892B2 (en)	2003-04-02	2009-11-24	Palm, Inc.	System and method for enabling a person to switch use of computing devices
WO2004089280A2 (en)	2003-04-08	2004-10-21	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
MXPA05010773A (en)	2003-04-09	2005-12-12	Neose Technologies Inc	Glycopegylation methods and proteins/peptides produced by the methods.
BRPI0412671A (en)	2003-08-08	2006-10-03	Fresenius Kabi De Gmbh	conjugates of a polymer and a protein linked by an oxime linking group
CN1832762B (en) *	2003-08-08	2012-09-05	弗雷泽纽斯卡比德国有限公司	Conjugates of hydroxyalkyl starch and g-csf
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
JP2007501811A (en)	2003-08-08	2007-02-01	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest.
WO2005016949A2 (en)	2003-08-12	2005-02-24	Lipoxen Technologies Limited	Sialic acid derivatives
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
JP4738346B2 (en)	2003-12-03	2011-08-03	ノヴォノルディスクアー／エス	GlycoPEGylated factor IX
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
KR101237884B1 (en)	2003-12-03	2013-02-27	바이오제너릭스 에이지	Glycopegylated granulocyte colony stimulating factor
BRPI0506741A (en)	2004-01-08	2007-05-15	Neose Technologies Inc	glycosylation of peptides linked to the
WO2005092369A2 (en)	2004-03-11	2005-10-06	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyethyl starch and erythropoietin
GB0412181D0 (en) *	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US20090292110A1 (en)	2004-07-23	2009-11-26	Defrees Shawn	Enzymatic modification of glycopeptides
JP2008507990A (en)	2004-08-02	2008-03-21	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Conjugate of FVII
EP1776389B1 (en)	2004-08-12	2016-06-29	Lipoxen Technologies Limited	Sialic acid derivatives
US8268967B2 (en)	2004-09-10	2012-09-18	Novo Nordisk A/S	Glycopegylated interferon α
LT3130601T (en)	2004-11-12	2020-09-10	Bayer Healthcare Llc	Site-directed modification of fviii
MX2007007590A (en)	2004-12-22	2007-12-10	Ambrx Inc	Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides.
PT1835938E (en)	2004-12-27	2013-11-06	Baxter Int	Polymer-von willebrand factor-conjugates
JP2008526864A (en)	2005-01-06	2008-07-24	ネオステクノロジーズインコーポレイテッド	Sugar linkage using sugar fragments
KR20080013850A (en) *	2005-02-08	2008-02-13	더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치	Immunogenic molecules
JP5216580B2 (en)	2005-05-25	2013-06-19	ノヴォノルディスクアー／エス	Glycopegylated factor IX
MX2007016314A (en)	2005-06-16	2008-03-10	Nektar Therapeutics Al Corp	Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates.
EP1893632B1 (en)	2005-06-17	2015-08-12	Novo Nordisk Health Care AG	Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
WO2007022784A2 (en)	2005-08-26	2007-03-01	Maxygen Holdings Ltd.	Liquid factor vii composition
AU2006286486A1 (en) *	2005-08-30	2007-03-08	Novo Nordisk Health Care Ag	Liquid formulations of pegylated growth hormone
EP1962907A2 (en)	2005-12-21	2008-09-03	Wyeth a Corporation of the State of Delaware	Protein formulations with reduced viscosity and uses thereof
KR20080108416A (en) *	2006-01-19	2008-12-15	암브룩스, 인코포레이티드	Non-natural amino acid polypeptides having modulated immunogenicity
AU2007245190B2 (en)	2006-03-31	2011-07-21	Takeda Pharmaceutical Company Limited	Pegylated factor VIII
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
EP2089052A4 (en)	2006-05-24	2011-02-16	Peg Biosciences	Peg linker compounds and biologically active conjugates thereof
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
US8097437B2 (en)	2006-07-13	2012-01-17	Serum Institute Of India Ltd.	Highly pure polysialic acid and process for preparation thereof
US20100056428A1 (en)	2006-09-01	2010-03-04	Novo Nordisk Health Care Ag	Modified proteins
EP2054521A4 (en)	2006-10-03	2012-12-19	Novo Nordisk As	Methods for the purification of polypeptide conjugates
CN101588820A (en) *	2006-11-17	2009-11-25	尼亚哈姆雷特药品公司	Alpha-lactalbumin composition
ES2521490T3 (en)	2006-12-15	2014-11-12	Baxter International Inc.	Conjugate of factor VIIa - (poly) sialic acid with a prolonged half-life in vivo.
WO2008083346A1 (en)	2006-12-28	2008-07-10	Ambrx, Inc.	Phenazine and quinoxaline substituted amino acids and polypeptides
EP2099475B1 (en)	2007-01-03	2016-08-24	Novo Nordisk Health Care AG	Subcutaneous administration of coagulation factor viia-related polypeptides
WO2008119815A1 (en)	2007-04-02	2008-10-09	Novo Nordisk A/S	Subcutaneous administration of coagulation factor ix
ES2644453T3 (en)	2007-06-26	2017-11-29	Baxalta GmbH	Fmoc polymeric hydrolysable connector
JP5702600B2 (en)	2007-07-03	2015-04-15	チルドレンズホスピタルアンドリサーチセンターアットオークランド	Oligosialic acid derivatives, production methods and immunological uses
US20100239517A1 (en)	2007-10-09	2010-09-23	Stephen Brocchini	Novel conjugated proteins and peptides
EP2070951A1 (en)	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Method for producing a hydroxyalkyl starch derivatives with two linkers
JP5647899B2 (en)	2008-01-08	2015-01-07	ラツィオファルムゲーエムベーハーｒａｔｉｏｐｈａｒｍＧｍｂＨ	Glycoconjugation of polypeptides using oligosaccharyltransferase
EP2257311B1 (en)	2008-02-27	2014-04-16	Novo Nordisk A/S	Conjugated factor viii molecules
CN102046205A (en)	2008-04-24	2011-05-04	凯尔特药物Peg有限公司	Factor IX conjugates with extended half-lives
JP5642065B2 (en)	2008-05-23	2014-12-17	ノボノルディスクヘルスケアアーゲー	Low viscosity composition comprising pegylated GLA-domain containing protein
CN102065899A (en)	2008-05-23	2011-05-18	诺沃-诺迪斯克保健股份有限公司	Formulations of PEG-functionalised serine proteases with high concentrations of an aromatic preservative
BRPI0913374A2 (en)	2008-06-04	2015-11-24	Bayer Healthcare Llc	fviii muteins for treatment of von willebrand disease
US8969626B2 (en)	2008-07-21	2015-03-03	Polytherics Limited	Reagents and method for conjugating biological molecules
CA2740793A1 (en)	2008-11-03	2010-06-03	Haiyan Jiang	Method for the treatment of hemophilia
WO2010083536A1 (en)	2009-01-19	2010-07-22	Bayer Healthcare Llc	Protein conjugate having an endopeptidase-cleavable bioprotective moiety
CN102333788A (en)	2009-02-19	2012-01-25	诺沃—诺迪斯克有限公司	Modification of factor viii
EP2403538B1 (en)	2009-03-04	2017-10-04	Polytherics Limited	Conjugated proteins and peptides
US20100330033A1 (en)	2009-04-16	2010-12-30	Nian Wu	Protein-carrier conjugates
EP2437786B1 (en)	2009-06-01	2016-05-18	Yeda Research and Development Co. Ltd.	Prodrugs containing albumin binding probe
CA2769258A1 (en)	2009-07-31	2011-02-03	Bayer Healthcare Llc	Modified factor ix polypeptides and uses thereof
DE102009028526A1 (en)	2009-08-13	2011-02-24	Leibniz-Institut Für Polymerforschung Dresden E.V.	Process for the modification and functionalization of saccharides
CA2775287A1 (en)	2009-09-25	2011-03-31	Vybion, Inc.	Polypeptide modification
CN102639553A (en)	2009-11-24	2012-08-15	诺沃—诺迪斯克保健股份有限公司	Method of purifying pegylated proteins
WO2011101277A1 (en)	2010-02-16	2011-08-25	Novo Nordisk A/S	Conjugated proteins
WO2011101242A1 (en)	2010-02-16	2011-08-25	Novo Nordisk A/S	Factor viii molecules with reduced vwf binding
GB201007357D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIII
GB201007356D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
DK2598172T3 (en)	2010-07-30	2019-07-01	Baxalta GmbH	Nucleophilic Catalysts for Oxygen Connection
US20130331554A1 (en)	2010-11-15	2013-12-12	Biogen Idec Inc.	Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
EA029045B1 (en)	2011-07-08	2018-02-28	Байоджен Хемофилия Инк.	Factor viii chimeric and hybrid polypeptides, and methods of use thereof

2011
- 2011-12-16 MX MX2013007369A patent/MX345608B/en active IP Right Grant
- 2011-12-16 DK DK11806103.5T patent/DK2654794T3/en active
- 2011-12-16 CN CN201180062472.4A patent/CN103269723B/en active Active
- 2011-12-16 CA CA2822591A patent/CA2822591C/en active Active
- 2011-12-16 SG SG2013048194A patent/SG191298A1/en unknown
- 2011-12-16 HU HUE11806103A patent/HUE049352T2/en unknown
- 2011-12-16 KR KR1020137019066A patent/KR102025442B1/en active IP Right Grant
- 2011-12-16 US US13/329,002 patent/US8945897B2/en active Active
- 2011-12-16 ES ES11806103T patent/ES2800983T3/en active Active
- 2011-12-16 EP EP11806103.5A patent/EP2654794B8/en active Active
- 2011-12-16 WO PCT/US2011/065591 patent/WO2012087838A1/en active Application Filing
- 2011-12-16 EP EP19211476.7A patent/EP3673921A1/en not_active Withdrawn
- 2011-12-16 PL PL11806103T patent/PL2654794T3/en unknown
- 2011-12-16 AU AU2011349574A patent/AU2011349574B9/en active Active
- 2011-12-16 PT PT118061035T patent/PT2654794T/en unknown
- 2011-12-16 BR BR112013015898-0A patent/BR112013015898A2/en not_active Application Discontinuation
- 2011-12-16 JP JP2013546263A patent/JP6138052B2/en active Active
- 2011-12-16 EA EA201390940A patent/EA032056B1/en unknown
- 2011-12-16 NZ NZ612320A patent/NZ612320A/en unknown
- 2011-12-21 TW TW100147675A patent/TWI546279B/en active
- 2011-12-22 AR ARP110104911A patent/AR084576A1/en active IP Right Grant
2017
- 2017-06-14 AU AU2017204019A patent/AU2017204019A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL2654794T3 (en)	2020-07-27
TWI546279B (en)	2016-08-21
JP6138052B2 (en)	2017-05-31
CN103269723A (en)	2013-08-28
AU2017204019A1 (en)	2017-07-06
EP3673921A1 (en)	2020-07-01
AU2011349574B2 (en)	2017-06-01
EA032056B1 (en)	2019-04-30
AR084576A1 (en)	2013-05-29
BR112013015898A2 (en)	2018-06-26
EA201390940A1 (en)	2014-04-30
MX2013007369A (en)	2013-09-26
AU2011349574A1 (en)	2013-07-11
CA2822591A1 (en)	2012-06-28
SG191298A1 (en)	2013-07-31
JP2014501262A (en)	2014-01-20
US20120190096A1 (en)	2012-07-26
DK2654794T3 (en)	2020-06-08
NZ612320A (en)	2015-06-26
KR102025442B1 (en)	2019-09-25
ES2800983T3 (en)	2021-01-07
MX345608B (en)	2017-02-07
PT2654794T (en)	2020-06-11
TW201305090A (en)	2013-02-01
HUE049352T2 (en)	2020-09-28
CN103269723B (en)	2017-04-05
US8945897B2 (en)	2015-02-03
WO2012087838A1 (en)	2012-06-28
EP2654794A1 (en)	2013-10-30
AU2011349574B9 (en)	2017-06-15
EP2654794B1 (en)	2020-03-04
KR20130129254A (en)	2013-11-27
CA2822591C (en)	2020-12-29

Legal Events

Date	Code	Title	Description
2013-09-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-10-30	17P	Request for examination filed	Effective date: 20130719
2013-10-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-04-02	DAX	Request for extension of the european patent (deleted)
2014-07-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1191220 Country of ref document: HK
2016-01-06	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BAXALTA INCORPORATED Owner name: BAXALTA GMBH
2017-06-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-07-12	17Q	First examination report despatched	Effective date: 20170608
2017-11-22	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BAXALTA GMBH Owner name: BAXALTA INCORPORATED
2019-03-26	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602011065400 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0047480000 Ipc: A61K0047540000
2019-04-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2019-04-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2019-05-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 47/54 20170101AFI20190326BHEP Ipc: A61P 7/00 20060101ALI20190326BHEP Ipc: A61K 47/60 20170101ALI20190326BHEP
2019-05-15	INTG	Intention to grant announced	Effective date: 20190423
2019-08-06	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2019-08-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-09-08	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2019-09-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2019-09-11	INTC	Intention to grant announced (deleted)
2019-10-09	INTG	Intention to grant announced	Effective date: 20190909
2020-01-06	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2020-01-31	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2020-01-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2020-03-04	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-03-04	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2020-03-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2020-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1239625 Country of ref document: AT Kind code of ref document: T Effective date: 20200315
2020-03-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602011065400 Country of ref document: DE
2020-04-01	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2020-04-07	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602011065400 Country of ref document: DE Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP Free format text: FORMER OWNERS: BAXALTA GMBH, ZUG, CH; BAXALTA INCORPORATED, BANNOCKBURN, ILL., US Ref country code: DE Ref legal event code: R081 Ref document number: 602011065400 Country of ref document: DE Owner name: TAKEDA PHARMACEUTICAL CO. LTD., JP Free format text: FORMER OWNERS: BAXALTA GMBH, ZUG, CH; BAXALTA INCORPORATED, BANNOCKBURN, ILL., US
2020-04-22	RAP2	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: BAXALTA INCORPORATED Owner name: BAXALTA GMBH
2020-06-01	REG	Reference to a national code	Ref country code: FI Ref legal event code: FGE
2020-06-08	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20200602
2020-06-11	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 2654794 Country of ref document: PT Date of ref document: 20200611 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20200601
2020-06-17	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2020-06-23	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2020-07-20	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20200304
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2020-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200605 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200604 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2020-09-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2020-09-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E049352 Country of ref document: HU
2020-09-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH
2020-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200704 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2020-12-07	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602011065400 Country of ref document: DE
2021-01-07	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2800983 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210107
2021-01-08	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2021-01-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2021-02-10	26N	No opposition filed	Effective date: 20201207
2021-02-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2021-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1239625 Country of ref document: AT Kind code of ref document: T Effective date: 20200304
2021-06-04	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602011065400 Country of ref document: DE Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP Free format text: FORMER OWNERS: BAXALTA GMBH, GLATTPARK, OPFIKON, CH; BAXALTA INCORPORATED, BANNOCKBURN, ILL., US Ref country code: DE Ref legal event code: R082 Ref document number: 602011065400 Country of ref document: DE Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602011065400 Country of ref document: DE Owner name: TAKEDA PHARMACEUTICAL CO. LTD., JP Free format text: FORMER OWNERS: BAXALTA GMBH, GLATTPARK, OPFIKON, CH; BAXALTA INCORPORATED, BANNOCKBURN, ILL., US
2021-07-27	REG	Reference to a national code	Ref country code: FI Ref legal event code: PCE Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED
2021-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2021-09-03	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20201231
2021-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: PC Ref document number: 1239625 Country of ref document: AT Kind code of ref document: T Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP Effective date: 20210719
2021-10-04	REG	Reference to a national code	Ref country code: NO Ref legal event code: CHAD Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP
2021-10-20	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20210923 AND 20210929
2021-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201216
2022-01-03	REG	Reference to a national code	Ref country code: ES Ref legal event code: PC2A Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED Effective date: 20211227
2022-02-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: PD Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: BAXALTA INCORPORATED Effective date: 20211222
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200304
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201231
2023-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20221122 Year of fee payment: 12
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230530
2023-07-26	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602011065400 Country of ref document: DE Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP Free format text: FORMER OWNER: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP
2023-12-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20231121 Year of fee payment: 13
2024-01-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20231124 Year of fee payment: 13
2024-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20231122 Year of fee payment: 13 Ref country code: SE Payment date: 20231121 Year of fee payment: 13 Ref country code: PT Payment date: 20231122 Year of fee payment: 13 Ref country code: NO Payment date: 20231123 Year of fee payment: 13 Ref country code: IE Payment date: 20231123 Year of fee payment: 13 Ref country code: HU Payment date: 20231204 Year of fee payment: 13 Ref country code: FR Payment date: 20231122 Year of fee payment: 13 Ref country code: FI Payment date: 20231121 Year of fee payment: 13 Ref country code: DK Payment date: 20231121 Year of fee payment: 13 Ref country code: DE Payment date: 20231121 Year of fee payment: 13 Ref country code: CZ Payment date: 20231124 Year of fee payment: 13 Ref country code: AT Payment date: 20231123 Year of fee payment: 13
2024-02-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20231127 Year of fee payment: 13
2024-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240102 Year of fee payment: 13
2024-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20240101 Year of fee payment: 13

Publication	Publication Date	Title
EP2654794B8 (en)	2020-04-22	Materials and methods for conjugating a water soluble fatty acid derivative to a protein
IL265707A (en)	2019-05-30	Pharmaceutical compositions comprising human antibodies to pcsk9
EP2576585B8 (en)	2016-12-21	Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
ZA201303544B (en)	2014-11-26	Compositions and methods for 3-hydroxypropionic acid production
AU2009299075A8 (en)	2011-06-09	Production of modified fatty acids in plants
EP2521447A4 (en)	2014-04-30	Fatty acid fumarate derivatives and their uses
EP2664328A4 (en)	2014-01-22	Omega3 fatty acid compound preparation
ZA201209596B (en)	2015-06-24	Napht-2-ylacetic acid derivatives to treat aids
EP2658837A4 (en)	2018-01-17	Glycerides and fatty acid mixtures and methods of using same
EP2648706A4 (en)	2014-07-23	Compositions and methods relating to proliferative diseases
EP2519636B8 (en)	2017-08-09	Production of hemagglutinin-neuraminidase protein in microalgae
EP2554169A4 (en)	2014-05-14	Pharmaceutical preparation comprising phenylalanine derivative
EP2644624A4 (en)	2014-06-04	6-deoxy-6-thioether-amino acid cyclodextrin derivatives and preparation method thereof
HK1166065A1 (en)	2012-10-19	Process for the preparation of propionic acid derivatives
IL225771A0 (en)	2013-06-27	Indole derivatives and process for their preparation
EP2625353A4 (en)	2017-02-15	Improvements to fencing
GB2480358B (en)	2015-01-14	Method for listening to ultrasonic animal sounds
ZA201109483B (en)	2012-09-26	Glycyrrhetinic acid ester derivative synthesis method and deoxoglycyrrhetinic acid ester compound
EP2545033A4 (en)	2013-08-21	Propionic acids, propionic acid esters, and related compounds
ZA201205062B (en)	2013-03-27	Process for the preparation of propionic acid derivatives
EP2533947A4 (en)	2017-06-28	Improvements in and relating to implements
PL389984A1 (en)	2011-07-04	Unit for measuring the speed of objects in relation to the ground
AU2010100004A4 (en)	2010-03-25	Ready to serve oysters
AU2010903057A0 (en)	2010-07-22	Acetylenation of fatty acids
HK1169392A1 (en)	2013-01-25	Method to prepare 3-acetylisoquinoline and derivatives thereof 3-